CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes

May 23, 2025

Publications

>

Note

No

CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes

Publicated to:Cardiovascular Diabetology. 2025; 24 (1): - - 2025-12-01 24(1), DOI: 10.1186/s12933-025-02700-0

Authors: Schnell O; Almandoz J; Anderson L; Barnard-Kelly K; Battelino T; Blüher M; Busetto L; Catrinou D; Ceriello A; Cos X; Danne T; Dayan CM; Del Prato S; Fernández-Fernández B; Fioretto P; Forst T; Gavin JR; Giorgino F; Groop PH; Harsch IA; Heerspink HJL; Heinemann L; Ibrahim M; Jadoul M; Jarvis S; Ji L; Kanumilli N; Kosiborod M; Landmesser U; Macieira S; Mankovsky B; Marx N; Mathieu C; McGowan B; Milenkovic T; Moser O; Müller-Wieland D; Papanas N; Patel DC; Pfeiffer AFH; Rahelić D; Rodbard HW; Rydén L; Schaeffner E; Spearman CW; Stirban A; Tacke F; Topsever P; Van Gaal L; Standl E

Affiliations

Acibadem Mehmet Ali Aydinlar Universitesi - Author

Asklepios Klinik Birkenwerder - Author

Cardiff University School of Medicine - Author

Charité – Universitätsmedizin Berlin - Author

Charité – Universitätsmedizin Berlin; Helmholtz Center Munich German Research Center for Environmental Health - Author

Clinical Hospital Merkur - Author

Cliniques Universitaires Saint-Luc - Author

CRS Clinical Research Services Mannheim GmbH - Author

Democritus University of Thrace - Author

Division of Endocrinology and Metabolism - Author

EDC - Author

Emory University School of Medicine - Author

Endocrine and Metabolic Consultants - Author

Faculty of Health Sciences, University of Cape Town - Author

Foundation University Institute for Primary Health Care Research Jordi Gol i Gorina - Author

General Practitioner - Author

Helmholtz Center Munich German Research Center for Environmental Health - Author

Helsingin Yliopisto; Folkhälsan; Monash University; Baker Heart and Diabetes Institute - Author

Hospital Universitario Fundación Jiménez Díaz; Facultad de Medicina de la Universidad Autónoma de Madrid - Author

IRCCS Multimedica - Author

Karolinska Institutet - Author

King's College London - Author

Manchester University NHS Foundation Trust - Author

NOVA Medical School - Faculdade de Ciências Médicas, Universidade Nova de Lisboa - Author

Ovidius University of Constanta - Author

Peking University People's Hospital - Author

Sant'Anna Scuola Universitaria Superiore Pisa - Author

Sciarc GmbH - Author

Science Consulting in Diabetes GmbH - Author

Shupyk National Healthcare University of Ukraine - Author

Southern Health NHS Foundation Trust - Author

St George’s, University of London; St George's University Hospitals NHS Foundation Trust - Author

UMKC School of Medicine - Author

Uniklinik RWTH Aachen - Author

Universita degli Studi di Bari Aldo Moro - Author

Universitá degli Studi di Padova - Author

Universitair Medisch Centrum Groningen - Author

Universitair Ziekenhuis Antwerpen - Author

Universität Bayreuth; Medizinische Universität Graz - Author

Universitätsklinikum Leipzig und Medizinische Fakultät; Universität Leipzig - Author

Université Catholique de Louvain - Author

University Clinic of Endocrinology; SS Cyril and Methodius University Faculty of Medicine - Author

University College London - Author

Univerzitetni Klinični Center Ljubljana; Univerza v Ljubljani Medicinska Fakulteta - Author

UT Southwestern Medical School - Author

Abstract

The 10th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on December 5–6, 2024. This year, discussions about cardiovascular (CV) and kidney outcome trials centered on the recent findings from studies involving empagliflozin (EMPACT-MI), semaglutide (STEP-HFpEF-DM and FLOW), tirzepatide (SURMOUNT-OSA and SUMMIT), and finerenone (FINEARTS-HF). These studies represent significant advances in reducing the risk of major adverse cardiovascular events (MACE) and improving metabolic outcomes in heart failure with preserved ejection fraction (HFpEF), chronic kidney disease (CKD), and obstructive sleep apnea (OSA). The congress also comprised sessions on novel and established therapies for managing HFpEF, CKD, and obesity; guidelines for managing CKD and metabolic dysfunction-associated steatotic liver disease (MASLD); organ crosstalk and the development of cardio-kidney-metabolic (CKM) syndrome; precision medicine and person-centered management of diabetes, obesity, cardiovascular disease (CVD) and CKD; early detection of type 1 diabetes (T1D) and strategies to delay its onset; continuous glucose monitoring (CGM) and automated insulin delivery (AID); cardiovascular autonomic neuropathy (CAN) and the diabetic heart; and the role of primary care in the early detection, prevention and management of CKM diseases. The contribution of environmental plastic pollution to CVD risk, the increasing understanding of the efficacy and safety of incretin therapies in the treatment of CKM diseases, and the latest updates on nutrition strategies for CKM management under incretin-based therapies were also topics of interest for a vast audience of endocrinologists, diabetologists, cardiologists, nephrologists and primary care physicians, who actively engaged in online discussions. The 11th CVOT Summit will be held virtually on November 20–21, 2025 (http://www.cvot.org).

Indexed in

License and use

Citations

Altmetrics

Analysis of institutional authors

Share

CVOT summit report 2024: new cardiovascular, kidney, and metabolic outcomes

Affiliations

Abstract

Keywords

Quality index

Impact and social visibility